Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group.

Pooja Hingorani,Mark Krailo,Allen Buxton,Paul R. Hutson,Justin Davis,Katherine A. Janeway,Richard Gorlick,Michael S. Isakoff

Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group.

2020

Pooja Hingorani
Mark Krailo
Allen Buxton
Paul R. Hutson
Justin Davis
Katherine A. Janeway
Richard Gorlick
Michael S. Isakoff

10508Background: Treatment of patients with recurrent osteosarcoma (OS) is challenging and novel effective therapies are urgently needed. This study evaluated disease control rate (DCR) in patients...

Keywords:

Oncology
Phases of clinical research
Internal medicine
Recurrent osteosarcoma
in patient
Antibody
Dinutuximab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations